JP2015518903A5 - - Google Patents

Download PDF

Info

Publication number
JP2015518903A5
JP2015518903A5 JP2015516256A JP2015516256A JP2015518903A5 JP 2015518903 A5 JP2015518903 A5 JP 2015518903A5 JP 2015516256 A JP2015516256 A JP 2015516256A JP 2015516256 A JP2015516256 A JP 2015516256A JP 2015518903 A5 JP2015518903 A5 JP 2015518903A5
Authority
JP
Japan
Prior art keywords
compound
acceptable salt
pharmaceutically acceptable
optionally substituted
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015516256A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015518903A (ja
JP6214643B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/044800 external-priority patent/WO2013185084A1/en
Publication of JP2015518903A publication Critical patent/JP2015518903A/ja
Publication of JP2015518903A5 publication Critical patent/JP2015518903A5/ja
Application granted granted Critical
Publication of JP6214643B2 publication Critical patent/JP6214643B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015516256A 2012-06-08 2013-06-07 ピリミジニルチロシンキナーゼ阻害剤 Expired - Fee Related JP6214643B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261657360P 2012-06-08 2012-06-08
US61/657,360 2012-06-08
PCT/US2013/044800 WO2013185084A1 (en) 2012-06-08 2013-06-07 Pyrimidinyl tyrosine kinase inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017150480A Division JP2017193583A (ja) 2012-06-08 2017-08-03 ピリミジニルチロシンキナーゼ阻害剤

Publications (3)

Publication Number Publication Date
JP2015518903A JP2015518903A (ja) 2015-07-06
JP2015518903A5 true JP2015518903A5 (https=) 2016-07-28
JP6214643B2 JP6214643B2 (ja) 2017-10-18

Family

ID=49712704

Family Applications (6)

Application Number Title Priority Date Filing Date
JP2015516256A Expired - Fee Related JP6214643B2 (ja) 2012-06-08 2013-06-07 ピリミジニルチロシンキナーゼ阻害剤
JP2017150480A Withdrawn JP2017193583A (ja) 2012-06-08 2017-08-03 ピリミジニルチロシンキナーゼ阻害剤
JP2019017850A Withdrawn JP2019077728A (ja) 2012-06-08 2019-02-04 ピリミジニルチロシンキナーゼ阻害剤
JP2021018127A Pending JP2021073298A (ja) 2012-06-08 2021-02-08 ピリミジニルチロシンキナーゼ阻害剤
JP2021018128A Pending JP2021073299A (ja) 2012-06-08 2021-02-08 ピリミジニルチロシンキナーゼ阻害剤
JP2023004462A Pending JP2023052415A (ja) 2012-06-08 2023-01-16 ピリミジニルチロシンキナーゼ阻害剤

Family Applications After (5)

Application Number Title Priority Date Filing Date
JP2017150480A Withdrawn JP2017193583A (ja) 2012-06-08 2017-08-03 ピリミジニルチロシンキナーゼ阻害剤
JP2019017850A Withdrawn JP2019077728A (ja) 2012-06-08 2019-02-04 ピリミジニルチロシンキナーゼ阻害剤
JP2021018127A Pending JP2021073298A (ja) 2012-06-08 2021-02-08 ピリミジニルチロシンキナーゼ阻害剤
JP2021018128A Pending JP2021073299A (ja) 2012-06-08 2021-02-08 ピリミジニルチロシンキナーゼ阻害剤
JP2023004462A Pending JP2023052415A (ja) 2012-06-08 2023-01-16 ピリミジニルチロシンキナーゼ阻害剤

Country Status (30)

Country Link
US (6) US9394277B2 (https=)
EP (3) EP3753934A1 (https=)
JP (6) JP6214643B2 (https=)
KR (4) KR20220154850A (https=)
CN (3) CN104540385B (https=)
AR (1) AR091273A1 (https=)
AU (5) AU2013271407B2 (https=)
BR (2) BR112014030655B1 (https=)
CA (2) CA3108186A1 (https=)
CY (1) CY1120638T1 (https=)
DK (1) DK2858499T3 (https=)
EA (2) EA027823B1 (https=)
ES (2) ES2684268T3 (https=)
HR (1) HRP20181294T1 (https=)
HU (1) HUE039897T2 (https=)
IL (2) IL235938B (https=)
IN (1) IN2014DN10576A (https=)
LT (1) LT2858499T (https=)
MX (2) MX363672B (https=)
NZ (1) NZ702715A (https=)
PH (2) PH12018501463B1 (https=)
PL (1) PL2858499T3 (https=)
PT (1) PT2858499T (https=)
RS (1) RS57978B1 (https=)
SG (2) SG11201408173WA (https=)
SI (1) SI2858499T1 (https=)
SM (1) SMT201800442T1 (https=)
TW (3) TWI719209B (https=)
WO (1) WO2013185084A1 (https=)
ZA (1) ZA201409255B (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ598985A (en) * 2009-09-04 2013-07-26 Biogen Idec Inc Bruton's tyrosine kinase inhibitors
WO2012058645A1 (en) 2010-10-29 2012-05-03 Biogen Idec Ma Inc. Heterocyclic tyrosine kinase inhibitors
US9353087B2 (en) 2012-06-08 2016-05-31 Biogen Ma Inc. Inhibitors of Bruton's tyrosine kinase
AR091273A1 (es) 2012-06-08 2015-01-21 Biogen Idec Inc Inhibidores de pirimidinil tirosina quinasa
AU2014362231B2 (en) * 2013-12-11 2019-04-04 Biogen Ma Inc. Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology
WO2015151006A1 (en) 2014-03-29 2015-10-08 Lupin Limited Substituted purine compounds as btk inhibitors
WO2015170266A1 (en) 2014-05-07 2015-11-12 Lupin Limited Substituted pyrimidine compounds as btk inhibitors
PE20190710A1 (es) * 2014-10-24 2019-05-17 Bristol Myers Squibb Co Compuestos de indol carboxamida utiles como inhibidores de cinasas
JP7214632B2 (ja) * 2016-07-21 2023-01-30 バイオジェン エムエー インク. ブルトン型チロシンキナーゼ阻害剤のコハク酸塩形態および組成物
WO2019208805A1 (ja) 2018-04-27 2019-10-31 小野薬品工業株式会社 Btk阻害活性を有する化合物を有効成分として含む自己免疫疾患の予防および/または治療剤
CN117285467A (zh) 2018-07-31 2023-12-26 罗索肿瘤学公司 喷雾干燥的分散体和制剂
EA202192575A1 (ru) 2019-03-21 2022-01-14 Онксео Соединения dbait в сочетании с ингибиторами киназ для лечения рака
CN114761006A (zh) 2019-11-08 2022-07-15 Inserm(法国国家健康医学研究院) 对激酶抑制剂产生耐药性的癌症的治疗方法
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
US20240100172A1 (en) 2020-12-21 2024-03-28 Hangzhou Jijing Pharmaceutical Technology Limited Methods and compounds for targeted autophagy
EP4313023A1 (en) 2021-04-02 2024-02-07 Biogen MA Inc. Combination treatment methods of multiple sclerosis
WO2023081709A1 (en) 2021-11-03 2023-05-11 Viracta Therapeutics, Inc. Vecabrutinib for the treatment of graft-versus-host disease
US20260083848A1 (en) 2021-11-03 2026-03-26 Viracta Therapeutics, Inc. Combination of car t-cell therapy with btk inhibitors and methods of use thereof
KR20240157639A (ko) 2021-12-14 2024-11-01 크로스파이어 온콜로지 홀딩 비.브이. 거대고리 btk 억제제
WO2024245577A1 (en) 2023-06-02 2024-12-05 Netherlands Translational Research Center Holding B.V. Therapeutic combinations of an irreversible btk inhibitor and a reversible btk inhibitor
WO2024246287A1 (en) 2023-06-02 2024-12-05 Crossfire Oncology Holding B.V. Medical use of a macrocyclic reversible btk inhibitor
WO2024245578A1 (en) 2023-06-02 2024-12-05 Netherlands Translational Research Center Holding B.V. Therapeutic combinations of an irreversible btk inhibitor and a macrocyclic reversible btk inhibitor
WO2024256568A1 (en) 2023-06-13 2024-12-19 Crossfire Oncology Holding B.V. Salt and crystal forms of a macrocyclic btk inhibitor
WO2024256574A1 (en) 2023-06-13 2024-12-19 Crossfire Oncology Holding B.V. Process for preparing macrocyclic btk inhibitors

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1624A (en) * 1840-06-10 Cooking-stove
US4528138A (en) 1984-06-20 1985-07-09 E. R. Squibb & Sons, Inc. 16-Keto-17-substituted thia-17-alkyl(or alkenyl or alkynyl) androstenes
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
JP2594486B2 (ja) 1991-01-15 1997-03-26 アルコン ラボラトリーズ インコーポレイテッド 局所的眼薬組成物
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
PA8474101A1 (es) 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
US6919178B2 (en) 2000-11-21 2005-07-19 Sunesis Pharmaceuticals, Inc. Extended tethering approach for rapid identification of ligands
IL151552A0 (en) 2000-03-17 2003-04-10 Bristol Myers Squibb Pharma Co Cyclic beta-amino acid derivatives as inhibitors of matrix metalloproteases and tnf-alpha
MY145722A (en) 2000-04-27 2012-03-30 Abbott Lab Diazabicyclic central nervous system active agents
ATE423120T1 (de) 2000-06-26 2009-03-15 Pfizer Prod Inc Pyrroloä2,3-düpyrimidin verbindungen als immunosuppressive wirkstoffe
PE20020507A1 (es) * 2000-10-17 2002-06-25 Schering Corp Compuestos no-imidazoles como antagonistas del receptor histamina h3
WO2003037271A2 (en) * 2001-10-30 2003-05-08 Millennium Pharmaceuticals,Inc. Compounds, pharmaceutical compositions and methods of use therefor
JP2005515173A (ja) 2001-10-31 2005-05-26 バイエル・ヘルスケア・アクチェンゲゼルシャフト ピリミド[4,5−b]インドール誘導体
MXPA05007485A (es) 2003-01-14 2006-01-30 Arena Pharm Inc Derivados de arilo y heteroarilo 1,2,3-trisubstituidos como moduladores del metabolismo y la profilaxis y tratamiento de trastornos relacionados con ello tales como diabetes e hiperglicemia.
JP4845736B2 (ja) 2003-10-14 2011-12-28 アリゾナ ボード オブ リージェンツ オン ビハーフ ザ ユニバーシティー オブ アリゾナ プロテインキナーゼ阻害剤
US20080253960A1 (en) * 2004-04-01 2008-10-16 The Trustees Of The University Of Pennsylvania Center For Technology Transfer Lipoprotein-Based Nanoplatforms
WO2005117909A2 (en) 2004-04-23 2005-12-15 Exelixis, Inc. Kinase modulators and methods of use
FR2870541B1 (fr) 2004-05-18 2006-07-14 Proskelia Sas Derives de pyrimidines antigonistes du recepteur de la vitronectine
AR050865A1 (es) 2004-09-09 2006-11-29 Sanofi Aventis Derivados de 2- morfolino-4-pirimidona
PT1812440E (pt) * 2004-11-04 2011-01-25 Vertex Pharma Pirazolo[1,5-a]pirimidinas úteis enquanto inibidores de proteínas cinases
CN102633730A (zh) 2004-12-03 2012-08-15 先灵公司 作为cb1拮抗剂的取代哌嗪
JP5274842B2 (ja) 2004-12-28 2013-08-28 エグゼリクシス, インコーポレイテッド 免疫疾患、炎症疾患および増殖疾患の処置のためのセリン−スレオニンキナーゼモジュレーター(p70S6K、Akt−1およびAkt−2)としての[1H−ピペラゾ[3,4−d]ピリミジン−4−イル]−ピペラジンまたは[1H−ピペラゾ[3,4−d]ピリミジン−4−イル]−ピペラジン化合物
WO2006071875A1 (en) 2004-12-29 2006-07-06 Millennium Pharmaceuticals, Inc. Compounds useful as chemokine receptor antagonists
WO2006091450A1 (en) * 2005-02-18 2006-08-31 Lexicon Genetics Incorporated 4-piperidin-1-yl-7h-pyrrolo[2,3-d]pyrimidine compounds
US20060281764A1 (en) 2005-06-10 2006-12-14 Gaul Michael D Aminopyrimidines as kinase modulators
US20060281700A1 (en) 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using aminopyrimidines kinase modulators
TW200740779A (en) 2005-07-22 2007-11-01 Mitsubishi Pharma Corp Intermediate compound for synthesizing pharmaceutical agent and production method thereof
JP5191391B2 (ja) 2005-11-01 2013-05-08 ターゲジェン インコーポレーティッド キナーゼのビ−アリールメタ−ピリミジン阻害剤
EP1965862A2 (en) * 2005-12-21 2008-09-10 Schering Corporation Combination of an h3 antagonist/inverse agonist and an appetite suppressant
WO2008005368A2 (en) 2006-06-30 2008-01-10 Abbott Laboratories Piperazines as p2x7 antagonists
WO2008012635A2 (en) 2006-07-26 2008-01-31 Pfizer Products Inc. Amine derivatives useful as anticancer agents
WO2008014307A2 (en) 2006-07-26 2008-01-31 Novartis Ag Inhibitors of undecaprenyl pyrophosphate synthase
WO2008033858A2 (en) * 2006-09-11 2008-03-20 Cgi Pharmaceuticals, Inc. Kinase inhibitors, and methods of using and identifying kinase inhibitors
DK2526933T3 (en) 2006-09-22 2015-05-18 Pharmacyclics Inc Inhibitors of Bruton's tyrosine kinase
JP2010520199A (ja) * 2007-03-02 2010-06-10 シェーリング コーポレイション ピペリジン誘導体およびその使用方法
CN101730699A (zh) 2007-03-21 2010-06-09 百时美施贵宝公司 可用于治疗增殖性、变应性、自身免疫性和炎症性疾病的稠合杂环化合物
WO2008144253A1 (en) 2007-05-14 2008-11-27 Irm Llc Protein kinase inhibitors and methods for using thereof
CN101932580B (zh) 2007-06-01 2013-05-22 葛兰素史密丝克莱恩有限责任公司 咪唑并吡啶激酶抑制剂
PL2242749T3 (pl) * 2008-02-05 2013-09-30 Hoffmann La Roche Nowe pirydynony i pirydazynony
JP2011519049A (ja) 2008-04-29 2011-06-30 イミューンエクサイト インコーポレイテッド 免疫調節組成物およびその使用方法
CA2730930C (en) 2008-07-16 2015-01-13 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors
WO2010068788A1 (en) * 2008-12-10 2010-06-17 Cgi Pharmaceuticals, Inc. Heterocyclic amides as btk inhibitors
US8084620B2 (en) * 2008-12-19 2011-12-27 Bristol-Myers Squibb Company Carbazole carboxamide compounds useful as kinase inhibitors
EP3828185B1 (en) * 2009-01-06 2024-11-20 Dana-Farber Cancer Institute, Inc. Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders
KR20120016662A (ko) 2009-05-25 2012-02-24 산도즈 아게 세프토비프롤 메도카릴의 제조 방법
EP2485589A4 (en) 2009-09-04 2013-02-06 Biogen Idec Inc HETEROARYL-BTK INHIBITORS
NZ598985A (en) 2009-09-04 2013-07-26 Biogen Idec Inc Bruton's tyrosine kinase inhibitors
US8685880B2 (en) * 2010-06-30 2014-04-01 Chevron U.S.A. Inc. On-site drying of aqueous salt for ionic liquid make-up
WO2012058645A1 (en) 2010-10-29 2012-05-03 Biogen Idec Ma Inc. Heterocyclic tyrosine kinase inhibitors
US9353087B2 (en) 2012-06-08 2016-05-31 Biogen Ma Inc. Inhibitors of Bruton's tyrosine kinase
AR091273A1 (es) 2012-06-08 2015-01-21 Biogen Idec Inc Inhibidores de pirimidinil tirosina quinasa
EP3444251B1 (en) 2013-12-11 2023-06-07 Biogen MA Inc. Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology
AU2014362231B2 (en) 2013-12-11 2019-04-04 Biogen Ma Inc. Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology
WO2016054627A1 (en) 2014-10-03 2016-04-07 Ohio State Innovation Foundation Biomarkers of bruton tyrosine kinase inhibitor resistance
JP7214632B2 (ja) * 2016-07-21 2023-01-30 バイオジェン エムエー インク. ブルトン型チロシンキナーゼ阻害剤のコハク酸塩形態および組成物

Similar Documents

Publication Publication Date Title
JP2015518903A5 (https=)
JP2018520455A5 (https=)
CY1124222T1 (el) Ενωσεις πυριδινονης-πυριδινυλιου υποκατεστημενες με μεθυλο/φθορο-πυριδινυλο-μεθοξυ και ενωσεις πυριδινονης-πυριδινυλιου υποκατεστημενες με φθορο-πυριδινυλο-μεθοξυ
JP2016536364A5 (https=)
RU2017125025A (ru) Конденсированные кольцевые гетероарильные соединения и их применение в качестве ингибиторов trk
JP2017536369A5 (https=)
JP2015535277A5 (https=)
JP2015181191A5 (https=)
BR112017011731A2 (pt) compósito, processo para produção de compósito, catalisador de síntese de amônia e processo de síntese de amônia
JP2013147496A5 (ja) 有機金属錯体
RU2017120274A (ru) Гетероарильные соединения в качестве ингибиторов irak и их применения
JP2010535722A5 (https=)
JP2017524733A5 (https=)
JP2019081762A5 (https=)
JP2016534134A5 (https=)
JP2019519587A5 (https=)
JO3501B1 (ar) مشتقات 5-{(بيبرازين - 1-يل)-3-أوكسو - بروبيل}- إيميدازوليدين-2، 4 - دايون كمثبطات ل adamts لمعالجة هشاشة العظام)
JP2017052761A5 (https=)
JP2015091935A5 (https=)
JP2017515919A5 (https=)
JP2015510508A5 (https=)
JP2019516739A5 (https=)
JP2014526533A5 (https=)
JP2021524487A5 (https=)
JP2014167003A5 (https=)